Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com



Growth: Good revenue growth rate 13.0%, there is acceleration compared to average historical growth rates 5.1%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -15.6%

Profitability: LTM EBITDA margin is positive, +19.0%. On average the margin is decreasing unsteadily. In the last quarter the company beat the estimated EPS, +4.4%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.19 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 2.4%. Free cash flow yield -8.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 28.6% higher than minimum and 24.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.8x by EV / Sales multiple , the company can be 38.1% overvalued

Insiders: For the last 3 months insiders sold company shares on $46.9 mln (-0.023% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (+1.6%)106.2
year average price 106.74  


year start price 123.62 2025-10-31

max close price 130.59 2025-11-14

min close price 82.56 2026-05-11

current price 106.20 2026-10-30
Common stocks: 1 746 881 140

Dividend Yield:  2.4%
FCF Yield LTM: -8.2%
EV / LTM EBITDA: 23.7x
EV / EBITDA annualized: 24.9x
Last revenue growth (y/y):  +13.0%
Last growth of EBITDA (y/y):  -13.0%
Historical revenue growth:  +5.1%
Historical growth of EBITDA:  +6.9%
EV / Sales: 4.5x
Margin (EBITDA LTM / Revenue): 19.0%
Fundamental value created in LTM:
Market Cap ($m): 182 671
Net Debt ($m): 27 504
EV (Enterprise Value): 210 175
Price to Book: 3.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-04reuters.com

Abbott recalls glucose sensors after seven deaths linked to faulty readings

2026-02-04247wallst.com

5 Goldman Sachs Top Stock Picks Have Huge Upside Potential and Pay Dividends

2026-02-02seekingalpha.com

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

2026-01-31fool.com

Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist

2026-01-25seekingalpha.com

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

2026-01-24marketbeat.com

Is Abbott's January Pullback a Good Time to Buy?

2026-01-24seekingalpha.com

Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity

2026-01-23zacks.com

Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?

2026-01-23forbes.com

Is The Fall In Abbott Stock Justified?

2026-01-23seekingalpha.com

Abbott Laboratories: Buy This Dividend King On Sale Now
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-31 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800
filingDate 2026-01-22 2025-02-21 2024-02-16 2023-02-17 2022-02-18 2021-02-19
acceptedDate 2026-01-22 02:35:00 2025-10-29 16:22:25 2025-07-30 16:14:29 2025-02-21 16:07:20 2024-10-31 17:14:00 2024-07-31 16:02:17 2024-05-02 16:11:10 2024-02-16 16:15:58 2023-11-01 16:07:32 2023-08-03 16:07:28 2023-05-04 16:03:45 2023-02-17 16:09:44 2022-11-01 16:06:19 2022-02-18 16:02:57 2021-02-19 16:10:04
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 44 328M 11 369M 11 142M 41 950M 10 635M 10 377M 9 964M 40 109M 10 143M 9 978M 9 747M 43 653M 10 410M 43 075M 34 608M
costOfRevenue 19 721M 5 031M 4 854M 20 625M 4 698M 4 570M 4 420M 20 072M 4 605M 4 483M 4 331M 21 330M 4 629M 19 861M 17 231M
grossProfit 24 607M 6 338M 6 288M 21 325M 5 937M 5 807M 5 544M 20 037M 5 538M 5 495M 5 416M 22 323M 5 781M 23 214M 17 377M
researchAndDevelopmentExpenses 2 955M 785M 732M 2 823M 713M 698M 679M 2 719M 672M 715M 654M 2 852M 782M 2 738M 2 418M
generalAndAdministrativeExpenses 12 378M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 12 378M 3 103M 3 093M 11 651M 2 895M 2 915M 2 943M 10 883M 2 601M 2 740M 2 762M 11 109M 2 731M 11 276M 9 668M
otherExpenses 1 253M 420M 411M 0 470M -471M -472M 0 83M 498M 491M 0 498M 0 0
operatingExpenses 16 586M 4 308M 4 236M 14 474M 4 078M 4 084M 4 094M 13 602M 3 798M 3 953M 3 907M 13 961M 4 011M 14 014M 12 086M
costAndExpenses 36 280M 9 339M 9 090M 35 099M 8 776M 8 654M 8 514M 33 674M 8 403M 8 436M 8 238M 35 291M 8 640M 33 875M 29 317M
netInterestIncome -111M -259M -313M -132M -367M -662M
interestIncome 230M 77M 71M 344M 91M 82M 80M 385M 69M 98M 101M 183M 55M 43M 46M
interestExpense 341M 44M 121M 603M 142M 58M 61M 698M 166M 61M 52M 315M 141M 410M 708M
depreciationAndAmortization 2 746M 791M 777M 3 218M 801M 805M 805M 3 243M 824M 674M 602M 3 267M 944M 3 538M 3 327M
ebitda 11 332M 3 015M 3 048M 10 834M 2 907M 2 638M 1 450M 10 605M 2 593M 2 216M 2 111M 11 888M 2 714M 12 159M 9 003M
ebit 8 586M 7 616M 7 362M 8 621M 8 621M 5 676M
nonOperatingIncomeExcludingInterest -538M -765M -927M -259M 579M -385M
operatingIncome 8 048M 2 030M 2 052M 6 825M 1 859M 1 723M 1 450M 6 435M 1 769M 1 542M 1 509M 8 362M 1 770M 9 200M 5 291M
totalOtherIncomeExpensesNet 418M 150M 98M 188M 81M -62M -14M 229M -98M 94M 53M -56M -12M -989M -323M
incomeBeforeTax 8 466M 2 180M 2 150M 7 013M 1 940M 1 607M 1 436M 6 664M 1 671M 1 636M 1 562M 8 306M 1 758M 8 211M 4 968M
incomeTaxExpense 1 942M 536M 371M -6 389M 294M 305M 211M 941M 235M 261M 244M 1 373M 323M 1 140M 497M
netIncomeFromContinuingOperations 6 524M 13 402M 5 723M 6 933M 7 071M 4 471M
netIncomeFromDiscontinuedOperations 0 0 0 0 0 24M
otherAdjustmentsToNetIncome 0 0 0 0 0 0
netIncome 6 524M 1 644M 1 779M 13 402M 1 646M 1 302M 1 225M 5 723M 1 436M 1 375M 1 318M 6 933M 1 435M 7 071M 4 495M
netIncomeDeductions 0 0 0 0 0 0
bottomLineNetIncome 6 524M 13 402M 5 723M 6 933M 7 071M 4 495M
eps 3.74 0.94 1.02 7.67 0.95 0.75 0.71 3.3 0.83 0.79 0.76 3.94 1.15 3.97 2.52
epsDiluted 3.72 7.64 3.27 3.91 3.94 2.5
weightedAverageShsOut 1 747M 1 749M 1 740M 1 732M 1 734M 1 734M 1 734M 1 734M 1 739M 1 739M 1 738M 1 753M 1 248M 1 775M 1 773M
weightedAverageShsOutDil 1 747M 1 749M 1 751M 1 748M 1 748M 1 751M 1 750M 1 749M 1 748M 1 750M 1 752M 1 764M 1 764M 1 789M 1 786M
fillingDate 2025-10-29 2025-07-30 2024-10-31 2024-07-31 2024-05-02 2023-11-01 2023-08-03 2023-05-04 2022-11-01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
grossProfitRatio 0.557 0.564 0.558 0.56 0.556 0.546 0.551 0.556 0.555
ebitdaratio 0.265 0.274 0.273 0.166 0.146 0.256 0.222 0.217 0.261
operatingIncomeRatio 0.179 0.184 0.175 0.166 0.146 0.174 0.155 0.155 0.17
incomeBeforeTaxRatio 0.192 0.193 0.182 0.155 0.144 0.165 0.164 0.16 0.169
netIncomeRatio 0.145 0.16 0.155 0.125 0.123 0.142 0.138 0.135 0.138
epsdiluted 0.94 1.01 0.94 0.74 0.7 0.82 0.78 0.75 0.81
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800
fillingDate 2025-10-29 2025-07-30 2025-04-30 2024-10-31 2024-07-31 2024-05-02 2023-11-01 2023-08-03 2023-05-04 2022-11-01
acceptedDate 2025-10-29 16:22:25 2025-07-30 16:14:29 2025-04-30 16:14:32 2025-02-21 16:07:20 2024-10-31 17:14:00 2024-07-31 16:02:17 2024-05-02 16:11:10 2024-02-16 16:15:58 2023-11-01 16:07:32 2023-08-03 16:07:28 2023-05-04 16:03:45 2023-02-17 16:09:44 2022-11-01 16:06:19 2022-02-18 16:02:57 2021-02-19 16:10:04
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 7 511M 6 951M 6 532M 7 616M 7 558M 6 987M 6 284M 6 896M 6 709M 7 835M 9 882M 9 882M 9 594M 9 799M 6 838M
shortTermInvestments 222M 331M 312M 351M 230M 232M 367M 383M 338M 320M 288M 288M 313M 450M 310M
cashAndShortTermInvestments 7 733M 7 282M 6 844M 7 967M 7 788M 7 219M 6 651M 7 279M 7 047M 8 155M 10 170M 10 170M 9 907M 10 249M 7 148M
netReceivables 10 398M 10 232M 7 327M 6 925M 9 201M 6 854M 6 605M 6 565M 8 967M 8 479M 8 172M 6 218M 6 408M 6 487M 6 414M
inventory 6 708M 6 954M 6 639M 6 194M 6 813M 6 814M 6 827M 6 570M 6 650M 6 871M 6 173M 6 173M 5 734M 5 157M 5 012M
otherCurrentAssets 0 0 2 343M 2 570M 0 4 254M 2 293M 2 256M 8 967M 8 479M 8 881M 2 663M 2 796M 2 346M 1 867M
totalCurrentAssets 24 839M 24 468M 23 153M 23 656M 23 802M 23 119M 22 376M 22 670M 22 664M 23 505M 25 224M 25 224M 24 845M 24 239M 20 441M
propertyPlantEquipmentNet 11 504M 11 395M 10 932M 11 733M 10 621M 10 233M 10 107M 11 276M 9 552M 9 449M 9 162M 10 278M 8 689M 10 112M 10 130M
goodwill 23 971M 23 952M 23 359M 23 108M 23 658M 23 308M 23 383M 23 679M 23 277M 23 258M 22 799M 22 799M 22 284M 23 231M 23 744M
intangibleAssets 5 594M 5 920M 6 261M 6 647M 7 352M 7 827M 8 296M 8 815M 9 282M 9 834M 10 454M 10 454M 10 850M 12 739M 14 784M
goodwillAndIntangibleAssets 29 565M 29 872M 29 620M 29 755M 31 010M 31 135M 31 679M 32 494M 32 559M 33 092M 33 253M 33 253M 33 134M 35 970M 38 528M
longTermInvestments 951M 958M 907M 886M 912M 877M 818M 799M 788M 799M 766M 766M 764M 903M 1 031M
taxAssets 0 0 0 0 0 7 653M 7 487M 0 6 527M 6 509M 6 033M 0 5 369M 0 0
otherNonCurrentAssets 17 318M 17 306M 16 836M 15 384M 8 011M 0 0 5 975M 0 0 0 4 917M 0 3 972M 2 418M
totalNonCurrentAssets 59 338M 59 531M 58 295M 57 758M 50 554M 49 898M 50 091M 50 544M 49 426M 49 849M 49 214M 49 214M 47 956M 50 957M 52 107M
otherAssets 4M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 84 181M 83 999M 81 448M 81 414M 74 356M 73 017M 72 467M 73 214M 72 090M 73 354M 74 438M 74 438M 72 801M 75 196M 72 548M
accountPayables 4 123M 4 306M 4 214M 4 195M 4 034M 4 125M 4 178M 4 295M 3 961M 4 211M 4 607M 4 607M 4 133M 4 408M 3 946M
shortTermDebt 1 345M 507M 506M 1 754M 2 154M 1 615M 2 010M 1 325M 1 051M 2 284M 2 251M 2 481M 1 117M 999M 461M
taxPayables 469M 390M 485M 594M 713M 601M 562M 492M 318M 273M 343M 343M 394M 306M 362M
deferredRevenue 0 0 0 0 0 601M 562M 0 318M 273M 0 0 0 0 0
otherCurrentLiabilities 8 645M 8 236M 7 799M 5 913M 8 001M 7 419M 7 271M 6 132M 7 712M 7 582M 8 631M 6 502M 8 115M 5 767M 5 722M
totalCurrentLiabilities 14 582M 13 439M 13 004M 14 157M 14 902M 13 760M 14 021M 13 841M 13 042M 14 350M 15 489M 15 489M 13 365M 13 105M 11 907M
longTermDebt 11 596M 12 930M 12 736M 12 625M 12 825M 13 139M 12 576M 13 599M 14 477M 14 562M 14 522M 14 522M 15 297M 17 296M 18 527M
deferredRevenueNonCurrent 0 0 0 0 0 -6 558M -6 827M 0 -6 877M -7 038M -7 417M 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 1 372M 0 6 558M 6 827M 1 218M 6 877M 7 038M 7 522M 1 841M 0 2 072M 2 146M
otherNonCurrentLiabilities 6 739M 6 801M 6 644M 4 463M 6 601M 6 558M 6 827M 4 780M 6 877M 7 038M 7 417M 4 738M 18 302M 5 743M 6 063M
totalNonCurrentLiabilities 18 335M 19 731M 19 380M 19 356M 19 426M 19 697M 19 403M 20 546M 21 354M 21 600M 22 044M 22 044M 23 552M 26 067M 27 638M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 -971M 0 0 0 0
capitalLeaseObligations 0 0 0 896M 0 0 0 949M 0 0 0 943M 8 255M 956M 902M
totalLiabilities 32 917M 33 170M 32 384M 33 513M 34 328M 33 457M 33 424M 34 387M 34 396M 35 950M 36 562M 37 533M 36 917M 39 172M 39 545M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 25 412M 25 284M 25 125M 25 153M 25 020M 24 858M 24 726M 24 869M 24 727M 24 612M 24 709M 24 709M 24 560M 24 470M 24 145M
retainedEarnings 49 103M 48 467M 47 715M 47 261M 39 056M 38 354M 38 011M 37 554M 36 920M 36 355M 35 868M 35 257M 35 115M 31 528M 27 627M
accumulatedOtherComprehensiveIncomeLoss -6 684M -6 576M -7 417M -7 906M -7 804M -8 135M -8 166M -7 839M -8 480M -8 071M -8 051M -8 051M -9 445M -8 374M -8 946M
othertotalStockholdersEquity -16 877M -16 610M -16 612M -16 476M -15 759M -15 761M -15 686M -15 722M 21 693M -14 555M
totalStockholdersEquity 50 954M 50 565M 48 811M 47 664M 39 796M 39 318M 38 810M 38 603M 37 481M 37 174M 74 219M 36 686M 35 675M 35 802M 32 784M
totalEquity 51 264M 50 829M 49 064M 47 901M 40 028M 39 560M 39 043M 38 827M 37 694M 37 404M 74 219M 36 905M 35 675M 36 024M 33 003M
totalLiabilitiesAndStockholdersEquity 84 181M 83 999M 81 448M 74 356M 73 017M 72 467M 72 090M 73 354M 74 438M 72 801M
minorityInterest 310M 264M 253M 237M 232M 242M 233M 224M 213M 230M 222M 219M 0 222M 219M
totalLiabilitiesAndTotalEquity 84 181M 83 999M 81 448M 81 414M 74 356M 73 017M 72 467M 73 214M 72 090M 73 354M 74 438M 74 438M 72 801M 75 196M 72 548M
totalInvestments 1 173M 1 289M 1 219M 1 237M 1 142M 1 109M 1 185M 1 182M 1 126M 1 119M 1 054M 1 054M 1 077M 1 353M 1 341M
totalDebt 12 941M 13 437M 13 242M 15 275M 14 979M 14 754M 14 586M 15 873M 15 528M 16 846M 16 773M 17 946M 16 414M 19 251M 19 890M
netDebt 5 430M 6 486M 6 710M 7 659M 7 421M 7 767M 8 302M 8 977M 8 819M 9 011M 6 891M 8 064M 6 820M 9 452M 13 052M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-16 2023-02-17 2022-02-18 2021-02-19
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 6 925M 6 565M 6 218M 6 487M 6 414M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 4 789M 4 787M 4 950M 4 714M 4 308M
otherPayables 594M 492M 343M 306M 362M
accruedExpenses 1 701M 1 597M 1 556M 1 625M 1 416M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 896M 949M 943M 956M 902M
treasuryStock -16 844M -15 981M -15 229M -11 822M -10 042M
additionalPaidInCapital 0 0 0 0 0
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800
fillingDate 2025-10-29 2025-07-30 2025-04-30 2024-10-31 2024-07-31 2024-05-02 2023-11-01 2023-08-03 2023-05-04 2022-11-01
acceptedDate 2025-10-29 16:22:25 2025-07-30 16:14:29 2025-04-30 16:14:32 2025-02-21 16:07:20 2024-10-31 17:14:00 2024-07-31 16:02:17 2024-05-02 16:11:10 2024-02-16 16:15:58 2023-11-01 16:07:32 2023-08-03 16:07:28 2023-05-04 16:03:45 2023-02-17 16:09:44 2022-11-01 16:06:19 2022-02-18 16:02:57 2021-02-19 16:10:04
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 1 644M 1 779M 1 325M 13 402M 1 640M 1 297M 1 220M 5 723M 1 436M 1 375M 1 318M 6 933M 1 435M 7 071M 4 495M
depreciationAndAmortization 791M 777M 756M 3 218M 801M 805M 805M 3 243M 824M 800M 806M 3 267M 815M 3 538M 3 327M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 120M 142M 289M 673M 117M 141M 304M 644M 117M 132M 281M 685M 123M 640M 546M
changeInWorkingCapital 11M -407M -517M -9 217M 141M -288M -1 309M -2 475M -321M -444M -186M -1 519M 336M -771M -892M
accountsReceivables -202M -410M -262M -691M 0 -325M -151M -356M -461M -196M 233M -68M 530M -383M -924M
inventory 213M 3M -255M -58M 220M -103M -410M -232M 140M -248M -419M -1 413M -194M -456M -493M
accountsPayables 0 0 0 356M 0 0 0 -760M 179M 0 0 420M 0 1 288M 1 766M
otherWorkingCapital 0 0 0 -8 824M -79M 140M -748M -1 127M -179M 0 186M -458M 0 -1 220M -1 241M
otherNonCashItems 221M -244M -436M 482M 6M 2 184M 2 480M 126M -179M -660M -1 076M 215M 71M 55M 425M
netCashProvidedByOperatingActivities 2 787M 2 047M 1 417M 8 558M 2 705M 1 960M 1 025M 7 261M 1 877M 1 203M 1 143M 9 581M 2 780M 10 533M 7 901M
investmentsInPropertyPlantAndEquipment -496M -502M -484M -2 207M 0 -533M -398M -2 202M -560M -507M -380M -1 777M -467M -1 885M -2 177M
acquisitionsNet -55M 0 0 1 000 000 -1 000 000 1 000 000 0 -837M -51M 0 0 48M 0 -53M 16M
purchasesOfInvestments 0 0 0 -169M 9M 28M -28M -159M -38M 0 -86M -185M 0 -173M -83M
salesMaturitiesOfInvestments 0 0 0 28M -40M 49M 0 43M 38M 0 0 152M 0 77M 10M
otherInvestingActivites 94M -80M 14M -562M 2M 1 000 000 -23M -706M 4M -17M
netCashUsedForInvestingActivites -457M -582M -470M -594M -453M -425M -634M -1 213M -462M -484M
debtRepayment -493M -15M -1 036M 43M 160M -127M -1 445M -2M 0 -1 000 000
commonStockIssued 0 0 0 0 0 134M 56M 0 0 0
commonStockRepurchased -305M -6M -280M -1 295M -751M -3M -226M -1 227M -2M -426M -540M -3 795M -798M -2 299M -403M
dividendsPaid -1 031M -1 029M -1 026M -960M -961M -957M -888M -890M -890M -826M
otherFinancingActivites 69M -47M 287M 92M 13M 7M -61M 29M 20M 82M
netCashUsedProvidedByFinancingActivities -1 760M -1 097M -2 055M -1 576M -791M -1 176M -2 340M -1 289M -1 410M -1 543M
effectOfForexChangesOnCash -10M 51M 24M -96M 36M -13M -36M -23M -29M -27M 8M -122M -96M -70M 71M
netChangeInCash 560M 419M -1 084M 720M 571M 703M -612M -2 986M -1 126M -1 326M -721M 83M 657M 2 961M 2 978M
cashAtEndOfPeriod 7 511M 6 951M 6 532M 7 616M 7 558M 6 987M 6 284M 6 896M 6 709M 7 835M 9 161M 9 882M 9 594M 9 799M 6 838M
cashAtBeginningOfPeriod 6 951M 6 532M 7 616M 6 896M 6 987M 6 284M 6 896M 9 882M 7 835M 9 161M 9 882M 9 799M 8 937M 6 838M 3 860M
operatingCashFlow 2 787M 2 047M 1 417M 8 558M 2 705M 1 960M 1 025M 7 261M 1 877M 1 203M 1 143M 9 581M 2 780M 10 533M 7 901M
capitalExpenditure -496M -502M -484M -2 207M -556M -533M -398M -2 202M -560M -507M -380M -1 777M -467M -1 885M -2 177M
freeCashFlow 2 291M 1 545M 933M 6 351M 2 149M 1 427M 627M 5 059M 1 317M 696M 763M 7 804M 2 313M 8 648M 5 724M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-16 2023-02-17 2022-02-18 2021-02-19
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 9M 22M 22M 26M 19M
netCashProvidedByInvestingActivities -2 338M -3 133M -1 740M -2 008M -2 215M
netDebtIssuance -537M -2 475M -699M -248M -50M
longTermNetDebtIssuance -437M -2 496M -746M -44M -52M
shortTermNetDebtIssuance -100M 21M 47M -204M 2M
netStockIssuance -1 295M -1 227M -3 795M -2 299M -403M
netCommonStockIssuance -1 295M -1 227M -3 795M -2 299M -403M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid -3 836M -3 556M -3 309M -3 202M -2 560M
commonDividendsPaid -3 836M -3 556M -3 309M -3 202M -2 560M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 264M 167M 167M 255M 234M
netCashProvidedByFinancingActivities -5 404M -7 091M -7 636M -5 494M -2 779M
incomeTaxesPaid 1 723M 1 475M 1 864M 1 941M 970M
interestPaid 604M 662M 563M 544M 549M

Earning call transcript

2025 q4
2026-01-22 ET (fiscal 2025 q4)
2025 q3
2025-10-15 ET (fiscal 2025 q3)
2025 q2
2025-07-17 ET (fiscal 2025 q2)
2025 q1
2025-04-16 ET (fiscal 2025 q1)
2024 q4
2025-01-22 ET (fiscal 2024 q4)
2024 q3
2024-10-16 ET (fiscal 2024 q3)
2024 q2
2024-07-18 ET (fiscal 2024 q2)
2024 q1
2024-04-17 ET (fiscal 2024 q1)
2023 q4
2024-01-24 ET (fiscal 2023 q4)
2023 q3
2023-10-18 ET (fiscal 2023 q3)
2023 q2
2023-07-20 ET (fiscal 2023 q2)
2023 q1
2023-04-19 ET (fiscal 2023 q1)
2022 q4
2023-01-25 ET (fiscal 2022 q4)
2022 q3
2022-10-19 ET (fiscal 2022 q3)
2022 q2
2022-07-20 ET (fiscal 2022 q2)
2022 q1
2022-04-20 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-07-16 11:30 ET
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
2026-06-25 ET
Abbott hosts conference call for second-quarter earnings
2026-06-24 ET
ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
2026-06-22 ET
New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents
2026-06-12 ET
Abbott declares 410th consecutive quarterly dividend
2026-06-08 ET
New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
2026-06-06 ET
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
2026-05-27 ET
Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
2026-05-27 ET
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
2026-05-26 ET
Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
2026-04-28 13:00 ET
Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform
2026-04-25 16:30 ET
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
2026-04-17 ET
New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
2026-04-16 ET
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
2026-04-09 ET
New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
2026-03-30 ET
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
2026-03-26 ET
Abbott hosts conference call for first-quarter earnings
2026-03-24 ET
John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening
2026-03-23 ET
Abbott completes acquisition of Exact Sciences
2026-03-20 ET
Abbott acquisition of Exact Sciences set to close on March 23, 2026
2026-03-12 ET
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
2026-03-11 ET
Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'
2026-02-20 ET
Abbott declares 409th consecutive quarterly dividend
2026-02-06 ET
Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation
2026-01-22 12:30 ET
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
2026-01-20 ET
Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms
2026-01-05 ET
Abbott hosts conference call for fourth-quarter earnings
2026-01-05 ET
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
2025-12-22 ET
Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
2025-12-18 ET
Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart
2025-12-12 ET
Abbott increases quarterly dividend for 54th consecutive year
2025-12-08 ET
Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
2025-12-06 ET
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives
2025-12-04 ET
Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
2025-11-20 ET
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
2025-11-04 ET
Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"
2025-10-15 11:30 ET
Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance
2025-09-24 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2025-09-19 ET
Abbott Declares 407th Consecutive Quarterly Dividend
2025-08-29 ET
Abbott's Navitor™ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis
2025-08-18 ET
Abbott and Big Ten Conference Rally Students, Alumni, and Fans to Save Lives and Win $1 Million for Their School by Donating Blood This College Football Season
2025-07-17 ET
Abbott Reports Second-Quarter 2025 Results
2025-07-15 ET
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
2025-06-26 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2025-06-20 ET
New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier
2025-06-13 ET
Abbott Declares 406th Consecutive Quarterly Dividend
2025-05-27 ET
Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery
2025-05-15 ET
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
2025-05-07 ET
Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent
2025-05-01 ET
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
2025-04-29 ET
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
2025-04-27 ET
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
2025-04-26 ET
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
2025-04-16 ET
Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance
2025-03-31 ET
New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve
2025-03-27 ET
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
2025-03-26 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2025-03-24 ET
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
2025-02-21 ET
Abbott Declares 405th Consecutive Quarterly Dividend
2025-02-04 ET
Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care
2025-01-22 ET
Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
2025-01-14 ET
PUBLIC HEALTH ADVOCACY INSTITUTE (PHAI) FILES CLASS ACTION AGAINST ABBOTT LABORATORIES OVER MARKETING OF "TODDLER MILK"
2025-01-02 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2024-12-17 ET
Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart
2024-12-13 ET
Abbott Increases Quarterly Dividend for 53rd Consecutive Year
2024-12-07 ET
University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott
2024-11-25 ET
Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis
2024-10-24 ET
Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure
2024-10-16 11:30 ET
Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range
2024-10-10 13:00 ET
Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping
2024-09-26 18:00 ET
Abbott and the Big Ten Conference Tackle U.S. Blood Shortages with First-of-its-Kind, Nationwide Blood Donation Competition, 'The We Give Blood Drive'
2024-09-25 13:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2024-09-19 16:59 ET
Abbott Declares 403rd Consecutive Quarterly Dividend
2024-09-05 13:00 ET
Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S.
2024-09-04 13:00 ET
Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression
2024-08-27 13:00 ET
Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores
2024-08-07 12:00 ET
Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices
2024-08-06 13:00 ET
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
2024-07-18 11:30 ET
Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance
2024-06-27 12:00 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2024-06-20 12:05 ET
Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health
2024-06-14 16:01 ET
Abbott Declares 402nd Consecutive Quarterly Dividend
2024-06-10 12:00 ET
Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
2024-06-03 13:00 ET
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
2024-04-29 13:00 ET
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
2024-04-17 11:30 ET
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
2024-04-02 13:00 ET
Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve
2024-04-01 13:00 ET
Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside
2024-03-27 20:30 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2024-03-06 14:00 ET
Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes
2024-02-16 15:19 ET
Abbott Declares 401st Consecutive Quarterly Dividend
2024-02-13 23:47 ET
FDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve
2024-02-01 14:00 ET
New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again
2024-01-31 14:00 ET
Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey
2024-01-25 14:00 ET
Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+
2024-01-24 12:30 ET
Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook
2024-01-18 14:00 ET
Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
2024-01-03 14:00 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2023-12-18 14:00 ET
Abbott to Present at J.P. Morgan Healthcare Conference
2023-12-15 16:25 ET
Abbott Increases Quarterly Dividend for 52nd Consecutive Year
2023-11-13 14:00 ET
Late-Breaking Data Show an Aspirin-Free Medication Regimen Benefits People with Abbott's HeartMate 3™ Heart Pump
2023-11-08 11:00 ET
Participants in Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes
2023-11-02 13:00 ET
Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV
2023-11-01 12:28 ET
Abbott and Sherri Shepherd: Millions Not Using Affordable Diabetes Technology
2023-11-01 ET
Abbott and Sherri Shepherd: Millions Not Using Affordable Diabetes Technology
2023-10-31 12:00 ET
Abbott and Damar Hamlin Team Up to Build Heart Health Community with New HeartMates Program
2023-10-26 13:00 ET
Ninety-One Percent of Young Adults With Student Loans Say Financial Stress is Impacting Their Wellness -- Abbott Launches Blueprint of Award-Winning Program to Help Companies Tackle This Problem
2023-10-25 18:30 ET
Late-Breaking Data Show Esprit™ BTK Drug-Eluting Resorbable Scaffold Reduces Chronic Limb-Threatening Ischemia Progression Compared to the Standard of Care
2023-10-24 22:18 ET
Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves
2023-10-18 11:30 ET
Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
2023-09-27 13:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2023-09-22 12:48 ET
Abbott Completes Acquisition of Bigfoot Biomedical
2023-09-21 16:02 ET
Abbott Declares 399th Consecutive Quarterly Dividend
2023-09-20 12:00 ET
Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets
2023-09-11 12:30 ET
Less Is More: Abbott’s Approach to Packaging Innovation
2023-09-05 20:30 ET
Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes
2023-07-20 11:30 ET
Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business
2023-07-05 13:00 ET
Abbott Receives FDA Approval for World's First Dual Chamber Leadless Pacemaker
2023-06-29 13:00 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2023-06-22 13:00 ET
Abbott's FreeStyle Libre® 2 Receives National Reimbursement in France for All People with Diabetes Who Use Insulin¹
2023-06-09 14:55 ET
Abbott Declares 398th Consecutive Quarterly Dividend
2023-05-31 13:00 ET
Abbott, Real Madrid and the Real Madrid Foundation Band Together to 'Beat Malnutrition' Globally Through New Campaign
2023-05-24 13:00 ET
European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations
2023-05-20 13:18 ET
Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints
2023-05-19 13:00 ET
Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm
2023-05-18 13:00 ET
Abbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term
2023-05-16 13:00 ET
Abbott Receives FDA Approval for Its Spinal Cord Stimulation Systems to Treat Chronic Back Pain in People Who Have Limited Surgical Options
2023-05-11 13:00 ET
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative
2023-04-27 20:10 ET
Abbott Completes Acquisition of Cardiovascular Systems, Inc.
2023-04-25 13:00 ET
Abbott's Life Support System Receives New FDA Clearances to Help Doctors Treat More Critically Ill Patients
2023-04-20 13:00 ET
Abbott and New Global Consortium Partnership Address Viral Outbreaks Caused by Climate Change
2023-04-19 11:15 ET
Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business
2023-04-17 12:00 ET
Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries
2023-04-14 13:00 ET
FDA Clears Reader for Abbott's FreeStyle Libre® 3 System
2023-03-29 13:00 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2023-03-23 13:00 ET
Don't Mess with Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get it Checked' in New Public Service Announcement
2023-03-07 14:00 ET
Abbott Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion
2023-03-06 12:00 ET
U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems
2023-03-05 14:07 ET
Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device
2023-03-04 15:41 ET
New Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation
2023-02-28 14:00 ET
Late-Breaking Data Reinforce Benefits of Abbott's Minimally Invasive Heart Devices
2023-02-17 17:26 ET
Abbott Declares 397th Consecutive Quarterly Dividend
2023-02-08 23:05 ET
Abbott to Acquire Cardiovascular Systems, Inc.
2023-01-26 14:00 ET
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
2023-01-25 12:30 ET
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
2023-01-17 14:00 ET
Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis
2023-01-07 02:00 ET
Abbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation
2023-01-04 14:00 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2022-12-21 14:00 ET
Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany
2022-12-20 14:00 ET
Abbott to Present at J.P. Morgan Healthcare Conference
2022-12-19 14:00 ET
Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain
2022-12-13 13:30 ET
Abbott and the Brain Injury Association of America launch Concussion Awareness Now coalition; team up with Rebel Wilson to raise awareness on seriousness of concussions
2022-12-09 15:48 ET
Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
2022-11-17 14:00 ET
Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
2022-10-28 13:00 ET
Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation
2022-10-19 11:30 ET
Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance
2022-10-12 13:42 ET
Abbott and The Home Edit Redesign the Medicine Cabinet to Help People Prepare for the Upcoming Virus Season
2022-10-06 13:00 ET
New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life
2022-09-28 13:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2022-09-17 18:45 ET
Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies
2022-09-15 16:56 ET
Abbott Declares 395th Consecutive Quarterly Dividend
2022-09-08 13:00 ET
Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery
2022-08-29 13:00 ET
New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
2022-08-23 13:00 ET
FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions
2022-08-11 13:00 ET
New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions
2022-08-04 20:10 ET
Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals
2022-07-20 11:30 ET
Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance
2022-07-12 13:00 ET
Abbott Receives FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression
2022-06-29 13:00 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2022-06-10 15:26 ET
Abbott Declares 394th Consecutive Quarterly Dividend
2022-06-05 13:00 ET
Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor
2022-06-03 13:00 ET
Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System
2022-05-31 12:00 ET
Abbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor
2022-05-27 16:05 ET
Diandra “Fu” Debrosse Zimmermann Becomes First Black Woman Ever Appointed to Lead a Multidistrict Litigation with Co-Lead Counsel Selection in Baby Formula MDL
2022-05-24 21:11 ET
Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need
2022-05-19 13:15 ET
New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies
2022-05-16 20:22 ET
Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility
2022-05-11 13:00 ET
Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials
2022-05-04 13:00 ET
Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
2022-04-29 20:35 ET
Abbott to Release Metabolic Nutrition Formulas
2022-04-29 13:00 ET
Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months
2022-04-28 13:00 ET
Abbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Company's Amulet™ Device
2022-04-28 11:00 ET
New Analysis Shows that Abbott's FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes
2022-04-27 12:00 ET
Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes
2022-04-26 13:00 ET
Abbott Recommends Rejection of Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
2022-04-25 13:00 ET
Abbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App
2022-04-20 11:30 ET
Abbott Reports First-Quarter 2022 Results
2022-04-04 13:00 ET
Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms
2022-03-30 11:30 ET
Abbott and LISC Team Up to Address Diversity and Equity Gaps in the Healthcare Industry Supply Chain
2022-03-28 13:00 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2022-03-24 13:00 ET
Abbott's FreeStyle® Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin
2022-02-21 14:00 ET
Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure
2022-02-18 16:26 ET
Abbott Declares 393rd Consecutive Quarterly Dividend
2022-02-17 22:11 ET
Abbott Voluntarily Recalls Powder Formulas Manufactured at One Plant
2022-02-07 14:00 ET
Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
2022-01-26 12:30 ET
Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast
2022-01-12 14:00 ET
Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms
2022-01-06 18:15 ET
Abbott Announces Future of Biowearables at Consumer Electronics Show
2022-01-04 22:00 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2022-01-04 14:00 ET
Abbott's Proclaim™ XR Spinal Cord Stimulation System Now Offers Expanded MRI Compatibility in U.S.
2021-12-21 14:00 ET
Abbott to Present at J.P. Morgan Healthcare Conference
2021-12-10 19:00 ET
Abbott Names Robert B. Ford Chairman of the Board; Miles D. White to Retire as Executive Chairman
2021-12-10 18:00 ET
Abbott Increases Quarterly Dividend for 50th Consecutive Year
2021-11-16 18:00 ET
Abbott Launches Similac® 360 Total Care® with Exclusive Blend of Five HMO Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development
2021-11-15 15:48 ET
Abbott Achieves Highest Score in Its Industry for the Ninth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
2021-11-12 14:00 ET
Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
2021-11-09 14:00 ET
Abbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology
2021-11-03 13:00 ET
Abbott Launches New Initiative to Drive Diversity in Medical Research and Improve Care Among Under-Represented Populations
2021-10-20 11:30 ET
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
2021-10-18 13:22 ET
Jason Sudeikis Joins Abbott, Real Madrid at New York Stock Exchange to Support Children's Health
2021-10-18 11:00 ET
Abbott and Real Madrid Team Up to Support the Health and Nutrition of Children Globally
2021-09-30 13:48 ET
Abbott Commits to Reducing Malnutrition Globally with Launch of Abbott Center for Malnutrition Solutions
2021-09-23 13:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2021-09-20 13:00 ET
Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease
2021-09-15 16:46 ET
Abbott Declares 391st Consecutive Quarterly Dividend
2021-09-02 13:30 ET
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
2021-08-30 15:55 ET
Late-Breaking Data Shows Abbott's Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke
2021-08-27 12:46 ET
GUIDE-HF Study Data Show Abbott's CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure
2021-08-18 14:46 ET
Podcast: How to Find STEM Success? Learn to Pivot.
2021-08-16 16:06 ET
Strengthening Resilience in Vulnerable Communities
2021-08-16 12:00 ET
Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
2021-08-13 13:51 ET
Abbott's Freestyle® Libre 2 IOS App Cleared In U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
2021-08-09 12:01 ET
A Workplace Where Collaboration = Innovation
2021-08-06 12:26 ET
A Convergence of Challenges: Addressing the Devastating Impact of Chronic Disease on Communities in Crisis
2021-08-04 14:11 ET
Broader Access is Vital to the Future of Testing and Healthcare Innovation
2021-08-03 13:00 ET
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
2021-08-02 13:00 ET
Abbott's FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
2021-07-29 13:00 ET
New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations
2021-07-23 15:42 ET
Building Trust and Improving Care in Underserved Communities
2021-07-22 11:15 ET
Abbott Reports Second-Quarter 2021 Results
2021-07-15 13:16 ET
Delivering Long-Term Impact: Abbott's 2020 Sustainability Report
2021-06-30 13:00 ET
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
2021-06-25 15:30 ET
Late-Breaking Data Demonstrate Abbott's FreeStyle® Libre System Supports Health Equity for Millions of Americans Living with Diabetes
2021-06-25 13:00 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2021-06-24 13:00 ET
People Who Exercise Intensely Could Improve Recovery by Adjusting Their Hydration Habits
2021-06-23 12:11 ET
Abbott Earns First-of-Its-Kind Recommendation for High School STEM Interns to Receive College Credit
2021-06-22 11:00 ET
Abbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit
2021-06-11 15:19 ET
Abbott Declares 390th Consecutive Quarterly Dividend
2021-06-03 11:00 ET
Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump
2021-06-01 12:00 ET
Abbott Issues Updated 2021 Outlook
2021-05-17 13:00 ET
Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis
2021-05-06 13:00 ET
Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
2021-04-20 11:30 ET
Abbott Reports First-Quarter 2021 Results
2021-04-19 12:30 ET
Abbott Begins Shipping BinaxNOW™ COVID-19 Ag Self Test to Retailers Today
2021-04-12 12:00 ET
World's Fastest Marathoner Eliud Kipchoge Uses Abbott's Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games
2021-04-08 13:00 ET
Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair
2021-04-06 13:00 ET
Abbott's XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients
2021-04-01 03:06 ET
Abbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use
2021-03-29 14:30 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2021-03-11 14:00 ET
Abbott Announces its Pandemic Defense Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Future Pandemics, Currently Searching for COVID-19 Variants
2021-03-08 14:00 ET
Abbott Introduces NeuroSphere™ Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S.
2021-03-05 14:00 ET
Abbott Receives FDA EUA for Laboratory PCR Assay That Detects and Differentiates SARS-CoV-2, Flu A, Flu B and RSV in One Test - and FDA EUA for Asymptomatic Usage of Alinity m COVID-19 Test
2021-03-02 12:45 ET
Abbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure
2021-02-19 18:26 ET
Abbott Declares 389th Consecutive Quarterly Dividend
2021-01-27 12:30 ET
Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021
2021-01-26 12:45 ET
Abbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab
2021-01-20 12:45 ET
Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device
2021-01-14 14:00 ET
Abbott to Launch the NeuroSphere™ myPath™ Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant
2021-01-12 14:00 ET
Abbott Announces Fulfillment of Federal Government Purchase of 150 Million BinaxNOW™ COVID-19 Rapid Tests and Is Now Ready to Support Commercial Distribution
2021-01-11 14:00 ET
Abbott Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions
2021-01-06 14:00 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2020-12-22 14:00 ET
As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner
2020-12-18 14:00 ET
Abbott to Present at J.P. Morgan Healthcare Conference
2020-12-17 21:52 ET
FDA Approves Labeling Update for Abbott's HeartMate 3 Heart Pump for use in Pediatric Patients
2020-12-16 17:55 ET
Abbott's BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMed's Digital Health Platform
2020-12-15 14:00 ET
Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test
2020-12-14 14:00 ET
Abbott Develops New Pedialyte® Hydration Solution to Help Support Immune Health
2020-12-11 16:00 ET
Abbott Increases Quarterly Dividend by 25%
2020-12-02 13:00 ET
Abbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms
2020-11-18 14:00 ET
Abbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes
2020-11-16 15:20 ET
Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)
2020-11-10 14:00 ET
Abbott Announces the U.S. Launch of the IonicRF™ Generator for Use in Patients Living With Chronic Pain
2020-10-30 13:00 ET
Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device
2020-10-21 11:30 ET
Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
2020-10-19 11:15 ET
Improved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows
2020-10-12 13:00 ET
Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test
2020-10-07 12:00 ET
Abbott Releases ID NOW™ COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health
2020-09-28 13:00 ET
Abbott's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes
2020-09-21 13:02 ET
Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation
2020-09-21 13:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2020-09-17 15:39 ET
Abbott Declares 387th Consecutive Quarterly Dividend
2020-09-17 13:00 ET
Abbott Introduces Libre Sense Glucose Sport Biosensor in Europe, World's First Glucose Biosensor Designed for Athletes
2020-09-03 13:00 ET
Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold
2020-09-01 13:00 ET
Abbott's FreeStyle® Libre 2 iCGM System Now Available to Medicare Beneficiaries
2020-08-26 22:30 ET
Abbott's Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization; Mobile App Displays Test Results to Help Our Return to Daily Life; Ramping Production to 50 Million Tests a Month
2020-08-04 13:00 ET
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
2020-07-23 13:00 ET
Abbott Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via Their Mobile Device
2020-07-16 11:30 ET
Abbott Reports Second-Quarter 2020 Results, Exceeds Analysts' Expectations
2020-07-13 20:15 ET
Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences
2020-07-06 11:30 ET
Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
2020-01-13 14:00 ET
Abbott to Initiate Trial to Study MitraClip as an Option for Moderate Surgical Risk Patients
2020-01-07 15:04 ET
FDA Approves Less Invasive Surgical Approach for Abbott's Heart Pump to Help Patients Avoid Open Heart Surgery
2019-12-13 15:39 ET
Abbott Raises Quarterly Dividend 12.5%, Increasing Payouts for 48 Straight Years
2019-11-13 12:45 ET
Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020
2019-11-06 13:37 ET
Abbott Announces Discovery of New Strain of HIV, Keeping Global Health Community a Step Ahead of the Virus
2019-10-21 13:00 ET
The Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening
2019-04-18 13:00 ET
Latin American Countries Offer Unique Benefits to Cannabis Cultivators
2019-04-11 19:16 ET
Abbott and the Abbott Fund Support Relief Efforts for Cyclone Idai
2019-03-20 13:00 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2019-03-19 12:00 ET
Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients

SEC forms

Show financial reports only

SEC form 8
2026-10-21 00:00 ET
Abbott reported for 2026 q3
SEC form 8
2026-10-21 00:00 ET
Abbott reported for 2026 q3
SEC form 8
2026-08-20 20:33 ET
Abbott published news for 2026 q2
SEC form 8
2026-08-20 20:33 ET
Abbott published news for 2026 q2
SEC form 10
2026-07-28 20:02 ET
Abbott published news for 2026 q2
SEC form 8
2026-07-16 11:36 ET
Abbott published news for 2026 q2
SEC form 8
2026-07-16 11:36 ET
Abbott published news for 2026 q2
SEC form 10
2026-04-29 20:05 ET
Abbott published news for 2026 q1
SEC form 8
2026-04-17 20:04 ET
Abbott published news for 2026 q1
SEC form 8
2026-04-17 20:04 ET
Abbott published news for 2026 q1
SEC form 8
2026-04-16 11:36 ET
Abbott published news for 2026 q1
SEC form 8
2026-04-16 11:36 ET
Abbott published news for 2026 q1
SEC form 8
2026-03-23 12:54 ET
Abbott published news for 2025 q4
SEC form 8
2026-03-23 12:54 ET
Abbott published news for 2025 q4
SEC form 8
2026-02-26 16:16 ET
Abbott published news for 2025 q4
SEC form 8
2026-02-26 16:16 ET
Abbott published news for 2025 q4
SEC form 8
2026-02-20 16:17 ET
Abbott published news for 2025 q4
SEC form 8
2026-02-20 16:17 ET
Abbott published news for 2025 q4
SEC form 10
2026-02-20 16:05 ET
Abbott reported for 2025 q4
SEC form 8
2026-01-22 07:35 ET
Abbott reported for 2025 q4
SEC form 8
2026-01-22 07:35 ET
Abbott reported for 2025 q4
SEC form 8
2025-11-21 16:06 ET
Abbott published news for 2025 q3
SEC form 8
2025-11-21 16:06 ET
Abbott published news for 2025 q3
SEC form 10
2025-10-29 20:22 ET
Abbott reported for 2025 q3
SEC form 8
2025-10-15 11:33 ET
Abbott reported for 2025 q3
SEC form 8
2025-10-15 11:33 ET
Abbott reported for 2025 q3
SEC form 10
2025-07-30 20:14 ET
Abbott reported for 2025 q2
SEC form 8
2025-07-17 00:00 ET
Abbott reported for 2025 q2
SEC form 8
2025-07-17 00:00 ET
Abbott reported for 2025 q2
SEC form 10
2025-04-30 20:14 ET
Abbott published news for 2025 q1
SEC form 10
2025-04-30 00:00 ET
Abbott reported for 2025 q1
SEC form 8
2025-04-16 11:36 ET
Abbott reported for 2025 q1
SEC form 8
2025-04-16 11:36 ET
Abbott reported for 2025 q1
SEC form 10
2025-02-21 21:07 ET
Abbott published news for 2024 q4
SEC form 10
2025-02-21 00:00 ET
Abbott reported for 2024 q4
SEC form 8
2025-01-22 07:13 ET
Abbott reported for 2024 q4
SEC form 8
2025-01-22 07:13 ET
Abbott published news for 2024 q4
SEC form 10
2024-10-31 00:00 ET
Abbott reported for 2024 q3
SEC form 8
2024-10-16 07:37 ET
Abbott published news for 2024 q3
SEC form 8
2024-10-16 07:37 ET
Abbott published news for 2024 q3
SEC form 10
2024-07-31 00:00 ET
Abbott reported for 2024 q2
SEC form 8
2024-07-18 07:37 ET
Abbott published news for 2024 q2
SEC form 8
2024-07-18 07:37 ET
Abbott published news for 2024 q2
SEC form 10
2024-05-02 00:00 ET
Abbott reported for 2024 q1
SEC form 8
2024-04-17 07:36 ET
Abbott reported for 2024 q1
SEC form 8
2024-04-17 07:36 ET
Abbott published news for 2024 q1
SEC form 10
2024-02-16 16:15 ET
Abbott reported for 2023 q4
SEC form 10
2024-02-16 00:00 ET
Abbott reported for 2023 q4
SEC form 8
2024-01-24 07:36 ET
Abbott published news for 2023 q4
SEC form 8
2024-01-24 07:36 ET
Abbott published news for 2023 q4
SEC form 10
2023-11-01 00:00 ET
Abbott reported for 2023 q3
SEC form 8
2023-10-18 07:37 ET
Abbott published news for 2023 q3
SEC form 10
2023-08-03 00:00 ET
Abbott reported for 2023 q2
SEC form 6
2023-07-20 08:29 ET
Abbott published news for 2023 q2
SEC form 8
2023-07-20 00:00 ET
Abbott published news for 2023 q2
SEC form 6
2023-06-23 16:07 ET
Abbott published news for 2023 q1
SEC form 6
2023-06-12 10:32 ET
Abbott published news for 2023 q1
SEC form 6
2023-06-09 16:05 ET
Abbott published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Abbott reported for 2023 q1
SEC form 8
2023-04-19 00:00 ET
Abbott published news for 2023 q1
SEC form 10
2023-02-17 00:00 ET
Abbott reported for 2022 q4
SEC form 8
2023-01-25 00:00 ET
Abbott reported for 2022 q4
SEC form 10
2022-11-01 00:00 ET
Abbott reported for 2022 q3
SEC form 8
2022-10-19 00:00 ET
Abbott reported for 2022 q3
SEC form 10
2022-08-02 00:00 ET
Abbott reported for 2022 q2
SEC form 8
2022-07-20 00:00 ET
Abbott published news for 2022 q2
SEC form 10
2022-05-03 00:00 ET
Abbott reported for 2022 q1
SEC form 8
2022-04-20 00:00 ET
Abbott reported for 2022 q1
SEC form 10
2022-02-18 00:00 ET
Abbott published news for 2021 q4
SEC form 8
2022-01-26 00:00 ET
Abbott published news for 2021 q4
SEC form 10
2021-11-03 00:00 ET
Abbott published news for 2021 q3
SEC form 8
2021-10-20 00:00 ET
Abbott published news for 2021 q3
SEC form 10
2021-08-04 00:00 ET
Abbott published news for 2021 q2
SEC form 8
2021-07-22 00:00 ET
Abbott published news for 2021 q2
SEC form 10
2021-05-05 00:00 ET
Abbott published news for 2021 q1
SEC form 8
2021-04-20 00:00 ET
Abbott published news for 2021 q1